Inhibrx Biosciences, Inc.
INBXHealthcareNASDAQBiotechnology · Last scanned Jul 16, 2026
Scan Results
Daily timeframeInhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. The $1.34B market capitalization puts INBX squarely in small-cap range for its industry. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
Market Cap
$1.34B
Beta
3.43
P/E (TTM)
—
P/E (Fwd)
-14.48
EPS (TTM)
$-8.23
EPS (Fwd)
$-6.30
ROE
-354.7%
ROA
-36.1%
Cash
$161.7M
Total Debt
$180.9M
Free CF
-$89.1M
52W Change
285.7%
Annual Financials
Cash vs Debt
Inhibrx Biosciences, Inc. carries $180.9M in total debt against $161.7M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$89.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -354.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $1.3M (2022) to $1.3M (2025).
Inhibrx Biosciences, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Inhibrx Biosciences, Inc.'s trajectory.